Cargando…
The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
BACKGROUND/AIMS: Arsenic trioxide (ATO) is the first-line therapeutic drug for acute promyelocytic leukemia. However, the cardiotoxicity of ATO limits its clinical application. This study aims to explore the long noncoding RNA (lncRNA) involved molecular mechanism in ATO-induced cardiotoxicity and t...
Autores principales: | Shen, Xiuyun, Zhi, Fengnan, Shi, Chunpeng, Xu, Jincheng, Chao, Yuqiu, Xu, Juan, Bai, Yunlong, Jiang, Yanan, Yang, Baofeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883885/ https://www.ncbi.nlm.nih.gov/pubmed/36707890 http://dx.doi.org/10.1186/s12967-023-03895-0 |
Ejemplares similares
-
Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
por: Shen, Xiuyun, et al.
Publicado: (2023) -
An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
por: Jiang, Yanan, et al.
Publicado: (2023) -
KCNQ1OT1 polymorphism rs35622507 and methylation status of KCNQ1OT1 promoter influence the drug resistance to L-OHP
por: Zhang, Caihong, et al.
Publicado: (2022) -
KCNQ1OT1 promotes melanoma growth and metastasis
por: Guo, Bingyu, et al.
Publicado: (2018) -
KCNQ1OT1: An Oncogenic Long Noncoding RNA
por: Cagle, Patrice, et al.
Publicado: (2021)